We usually look for negative EVs after a prolonged sector drought. But we've had good sector performance since November, with exception of a recent rough spot.
Matt Gamber at Twitter has looked for negative EVs under these circumstances.....
twitter.com
(thread)
Of those issues he mentions, I took a position in CMRX. Yeah, the same CMRX that brought such CMV-related misery to investors.
ONC201 for recurrent H3 K27M-mutant high-grade glioma, a molecule derived from the Oncoceutics munch. Observed toxicity in trials to date, but nothing that has derailed it.
https://aacrjournals.org/cancerdiscovery/article/13/11/2370/729854/Clinical-Efficacy-of-ONC201-in-H3K27M-Mutant
This position was taken without knowledge of market size, the difficulty penetrating it, or competitors addressing it. |
